Financial Contrast: CytRx (NASDAQ:CYTR) vs. Allogene Therapeutics (NASDAQ:ALLO)

Allogene Therapeutics (NASDAQ:ALLO) and CytRx (NASDAQ:CYTR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.

Profitability

This table compares Allogene Therapeutics and CytRx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Allogene Therapeutics N/A N/A N/A
CytRx N/A -34.37% -24.73%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Allogene Therapeutics and CytRx, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allogene Therapeutics 0 4 7 0 2.64
CytRx 0 0 1 0 3.00

Allogene Therapeutics currently has a consensus price target of $36.13, indicating a potential upside of 34.54%. CytRx has a consensus price target of $5.00, indicating a potential upside of 1,349.28%. Given CytRx’s stronger consensus rating and higher possible upside, analysts clearly believe CytRx is more favorable than Allogene Therapeutics.

Valuation and Earnings

This table compares Allogene Therapeutics and CytRx’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allogene Therapeutics N/A N/A -$211.51 million ($6.58) -4.08
CytRx $250,000.00 46.42 -$12.71 million ($0.29) -1.19

CytRx has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than CytRx, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

53.5% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of CytRx shares are owned by institutional investors. 36.5% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 6.6% of CytRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

CytRx beats Allogene Therapeutics on 6 of the 11 factors compared between the two stocks.

About Allogene Therapeutics

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company was founded in 2017 and is headquartered in South San Francisco, California.

About CytRx

CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.